CLEVELAND--(BUSINESS WIRE)--Prognostix Inc., a Cleveland Clinic spin-out company focused on cardiovascular disease testing and management, today announced that it has been awarded a $550,000 grant to support the continuing development and commercialization of its FDA-cleared CardioMPO™ test and its novel dysfunctional HDL product candidate.
